When orally administrated with EcN and EcN‐GLP‐1, the level of colon inflammation dropped significantly compared to that of exenatide, which means that the better therapeutic effects might benefit more from the probiotic properties of EcN.35, 39. Here, GLP1R is linked to digestive system neoplasm.